Literature DB >> 1473342

APIS: a software for model identification, simulation and dosage regimen calculations in clinical and experimental pharmacokinetics.

A Iliadis1, A C Brown, M L Huggins.   

Abstract

APIS is a software package based on mathematical modelling which provides a reliable approach in optimizing drug therapy. It was designed to assist clinicians in interpreting blood drug levels so that drug therapy may be better and more cost-effective. It is a methodological approach to describe, predict and control the kinetic behaviour of a drug. This software incorporates the principle of Bayesian procedures, i.e. one can use all available patient information (population) to determine patient-specific parameter estimates. These estimates can then be used to design an optimal and individualized drug regimen. APIS is an attractive and useful tool for clinical and experimental pharmacokinetics. APIS may be used on any IBM compatible computer using the Microsoft-Windows environment. The software is menu driven to provide a very user-friendly tool for analysing pharmacokinetic data and for designing dosage regimens.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1473342     DOI: 10.1016/0169-2607(92)90103-e

Source DB:  PubMed          Journal:  Comput Methods Programs Biomed        ISSN: 0169-2607            Impact factor:   5.428


  15 in total

1.  Information tools for exploratory data analysis in population pharmacokinetics.

Authors:  O Petricoul; L Claret; D Barbolosi; A Iliadis; C Puozzo
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-12       Impact factor: 2.745

2.  Intrarectal pharmacokinetics of two formulations of quinine in children with falciparum malaria.

Authors:  H Barennes; H Sterlingot; N Nagot; H Meda; M Kaboré; M Sanou; B Nacro; P Bourée; E Pussard
Journal:  Eur J Clin Pharmacol       Date:  2003-01-29       Impact factor: 2.953

3.  Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation.

Authors:  M-A Estève; B Devictor-Pierre; G Galy; N André; C Coze; B Lacarelle; J-L Bernard; S Monjanel-Mouterde
Journal:  Eur J Clin Pharmacol       Date:  2006-11-18       Impact factor: 2.953

4.  Effects of two oral erythromycin ethylsuccinate formulations on the motility of the small intestine in human beings.

Authors:  F Caron; M Bouaniche; F Delatour; P Ducrotte; J C Torlotin; P Denis; G Humbert; B Rouveix
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

5.  Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model.

Authors:  J P Bédos; V Rieux; J Bauchet; M Muffat-Joly; C Carbon; E Azoulay-Dupuis
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

6.  Efficacy of single-dose ceftriaxone in experimental otitis media induced by penicillin- and cephalosporin-resistant Streptococcus pneumoniae.

Authors:  B Barry; M Muffat-Joly; J Bauchet; F Faurisson; P Gehanno; J J Pocidalo; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

7.  Bayesian design criteria: computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model.

Authors:  Y Merlé; F Mentré
Journal:  J Pharmacokinet Biopharm       Date:  1995-02

8.  Kinetic nomograms assist individualization of drug regimens.

Authors:  Hafedh Marouani; Anastasios Zografidis; Athanassios Iliadis
Journal:  Clin Pharmacokinet       Date:  2011-12-01       Impact factor: 6.447

9.  Penetration of ciprofloxacin into bronchial secretions from mechanically ventilated patients with nosocomial bronchopneumonia.

Authors:  P Saux; C Martin; M N Mallet; L Papazian; B Bruguerolle; P De Micco; F Gouin
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

10.  Quinine distribution in mice with Plasmodium berghei malaria.

Authors:  Eric Pussard; Alexandra Bernier; Elyane Fouquet; Patrice Bouree
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Jan-Mar       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.